| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atherosclerosis and Lipoproteins |
From the A.I. Virtanen Institute (T.T.T., A.K., J.R., H.V., M.R., T.T.R., S.Y.-H.), Department of Medicine (S.Y.-H.), Gene Therapy Unit (S.Y.-H.), and Department of Pathology (K.K.), University of Kuopio, Kuopio, Finland; Franz Volhard Clinic, Charité, Humboldt University Hospital (J.H.B.), Berlin, Germany; Cardiovascular Surgery, University Hospital Eppendorf (Z.K.), Hamburg, Germany; Max-Delbrück-Centrum für Molekulare Medizin & Institut für Pathologie, Universitätsklinikum Charité (K.K.), Berlin, Germany.
Correspondence to Seppo Ylä-Herttuala, MD, PhD, FESC, Professor of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland. E-mail Seppo.Ylaherttuala{at}uku.fi
| Abstract |
|---|
|
|
|---|
Methods and Results We used laser microdissection (LMD) to isolate macrophage-rich shoulder areas from human lesions. Gene expression profiles in isolated cells were analyzed by cDNA array and compared with expression patterns in normal intima and THP-1 macrophages. Upregulation of 72 genes was detected with LMD and included 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, interferon regulatory factor-5 (IRF-5), colony stimulating factor (CSF) receptors, CD11a/CD18 integrins, interleukin receptors, CD43, calmodulin, nitric oxide synthase (NOS), and extracellular superoxide dismutase (SOD). Several of these changes were also present in PMA-stimulated THP-1 macrophages in vitro. On the other hand, expression of several genes, such as VEGF, tissue factor pathway inhibitor 2, and apolipoproteins C-I and C-II, decreased.
Conclusions Overexpression of HMG-CoA reductase in macrophage-rich lesion areas may explain some beneficial effects of statins, which can also modulate increased expression of CD11a/CD18 and CD43 found in microdissected cells. We also found increased expression of CSF receptors, IRF-5, and interleukin receptors, which could become useful therapeutic targets for the treatment of atherosclerotic diseases.
Key Words: atherosclerosis genes molecular biology plaque macrophages
| Introduction |
|---|
|
|
|---|
See cover
We have used LMD to isolate macrophage-rich shoulder areas from human atherosclerotic lesions and compared their gene expression patterns to macroscopically normal diffuse intimal thickening (DIT) by a cDNA array. Expression of several genes, such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, was increased in lesion macrophages. The results may help in the identification and validation of treatment targets for cardiovascular diseases.
| Materials and Methods |
|---|
|
|
|---|
|
Histology and Laser Microdissection
Paraffin sections were used for immunostainings for macrophages (CD68), T cells (CD3), endothelia (CD31), and SMCs (HHF35; all monoclonal antibodies from Dako Co.).11 Controls included incubations where primary antibodies were omitted and incubations with class- and species-matched irrelevant immunoglobulins.11
For LMD, 7-µm-thick OCT sections were used. Sections were fixed in 70% ethanol and counterstained with hematoxylin/eosin and dehydrated in graded ethanol and xylene. Macrophage-rich shoulder areas, adjacent lesion cap areas containing no inflammatory cells, and areas of macroscopically normal DIT were dissected (Leica DM LMD system, Leica) from the same individuals.12
Cell Culture
Human monocytic THP-1 cells (ATCC TIB-202) were cultured in RPMI1640 medium according to ATCC instructions. Cells were stimulated with 0.1 µmol/L PMA (Sigma) to induce differentiation into macrophages and collected at indicated time points. THP-1 cells were also similarly activated with PMA and incubated with 100 µg/mL oxidized LDL (Ox-LDL) for 72 hours.13
RNA Isolation
Total RNA was isolated from LMD samples using the Strataprep total RNA microprep kit (Stratagene) and was extracted from cultured cells using Trizol reagent (Gibco BRL). RNA was pooled from two independent cell culture experiments at each time point.
DNA Array Analysis
RNA from LMD cells was quantified with the RiboGreen RNA quantitation kit (Molecular Probes). 100 ng RNA was used for amplification. Amplification was done with T7 polymerase using three cycles as described elsewhere.14 Probes were prepared from 2.0 µg of amplified RNA, random hexamers, and Cy3-dCTP or Cy5-dCTP. The probes were hybridized as described on the Wellcome Trust Sanger Institute web site (http://www.sanger.ac.uk) to microarrays (Sanger center Hver1.2.1) containing approximately 10000 clones from the Integrated Molecular Analysis of Genomes and their Expression (I.M.A.G.E.) Consortium collection, representing approximately 6000 different genes. 50 µg of total RNA from cultured cells was labeled with Cy3-dCTP or Cy5-dCTP. All analyses were repeated three times, including the use of reversed fluorophores. Quantification of signals was performed with QuantArray software (GSI Lumonics), and the background was subtracted from the signal intensities. The linearity of the signal intensities was checked using GeneSpring software (Silicon Genetics) with M-A plot, where M represents the log ratio of the test and control samples and the A is the total log intensity of each spot. Because the data were linear (ie, blot displayed 45° rotation), normalization to the median of the signals was allowed, according to the protocol of the Finnish Center for Scientific Calculation.15 Signals were normalized using GeneSpring software by dividing each gene by the median of its measurements in all samples, and intensity ratios were calculated. Gene expression was considered significantly up- or downregulated when the intensity ratio test/control was
2.0 or
0.5, respectively. Statistical significance of the differences was calculated according to Claverie.16 To reach the 5% significance level ||Inttest-Intcontrol|| must be
2.8
control when analyzed in triplicates, where Inttest and Intcontrol are the averages of normalized signal intensities in test and control samples in repeated experiments and
is the distribution of signal intensities in the control sample.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
DNAase treatment and cDNA synthesis were performed as described.17 Primers for HMG-CoA reductase were 5'-ACAGGATGCAGCACA GAATG-3' and 5'-CTTTGCATGCTCCTTGAACA-3'. The PCR reaction consisted of 25 cycles of +94°C for 1 minute, +60°C for 1 minute, and +72°C for 90 seconds. Similarly, RT-PCRs were performed for ß-actin (5'-CTCTTCCAGCCTTCCTTCCT-3' and 5-TCTGCTTGCTGATCCACATC-3'), interferon regulatory factor-5 (IRF-5) (5'-TCTTCTGCTTTGGGGAAGAA-3' and 5'-GATGGAG CTCCTTGAATTGC-3'), VEGF (5'-CCCACTGAGGAGTCCAAC AT-3' and 5'-GCGAGTCTGTGTTTTTGCAG-3'), nitric oxide synthase (NOS) (5'-GCTCTCCGTGTAGCCTGAAG-3' and 5'-ACCGCAAGAATGATGTCTCC-3') and extracellular superoxide dismutase (GC-SOD) (5'-GAGCTTCTCCTCTGCTCCAA-3' and 5'-GGGAAGATCGTCAGGTCAAA-3').
| Results |
|---|
|
|
|---|
|
|
Comparison of Gene Expression in LMD Lesion Cells and Cultured Macrophages
Table 3
presents 62 genes that had altered expression levels in LMD samples and were not previously connected to atherosclerosis as primary products of macrophages. Genes were classified into functional classes as described previously18 and compared with PMA-treated THP-1 macrophages. Table 3
lists genes where changes (either
2.0-fold or
0.5-fold change) in gene expression profiles were seen in both lesion LMD cells and in PMA-stimulated THP-1 macrophages. Among these were several genes that have a role in signal transduction, for example, serine/threonine protein kinase, calmodulin and adenylate cyclase 7, cytochromes, calponins, and extracellular SOD. Interestingly, HMG-CoA reductase, which is involved in cholesterol biosynthesis, was highly upregulated in lesion macrophage-rich areas. In addition, several KIAA proteins that had unknown functions were up- or downregulated. The expression of HMG-CoA reductase was confirmed by RT-PCR in LMD fractions and PMA-stimulated macrophages (Figure 2). However, HMG-CoA reductase was not induced in Ox-LDL-treated, lipid-loaded THP-1 cells. In addition, the induction of IRF-5, NOS, and extracellular SOD and the downregulation of VEGF were confirmed by RT-PCR (Figure 2).
|
|
|
| Discussion |
|---|
|
|
|---|
Upregulation of a total of 72 genes was identified; 33 genes were previously connected to atherosclerosis and 39 were not. Twenty-three genes were downregulated. LMD results are based on the amplification of a small amount of RNA from individual samples, followed by DNA array analysis and standardization of the gene expression ratios using the GeneSpring program. Every effort was made to avoid any systematic bias in the results. However, we cannot totally exclude the possibility of some bias or that some important genes were not picked up by the analysis.
Upregulation of several important genes was detected. One of these was HMG-CoA reductase, which is a key enzyme in cholesterol biosynthesis.20 It was highly upregulated in LMD samples. The reason for the high expression level may be due to the proliferation and/or differentiation of macrophages because similar findings were obtained from PMA-stimulated THP-1 macrophages. Interestingly, it has been reported that HMG-CoA reductase in macrophages is not very sensitive to downregulation by cholesterol derived from LDL,21 which together with the low prevalence of lipid-loaded foam cells (<5%) in the analyzed LMD fractions may contribute to these findings. On the other hand, when THP-1 macrophages were incubated in the presence of Ox-LDL, downregulation of the HMG-CoA reductase was observed, which indicates that lipid-loaded THP-1 macrophages may not be an accurate model of macrophages present in shoulder areas. However, further studies are needed to clarify these issues.
It has been suggested that HMG-CoA reductase inhibitors, statins, have several beneficial effects that are not directly related to their cholesterol-lowering effects.22 Even though this hypothesis of the pleiotrophic effects of statins has not yet been fully tested, it is possible that macrophage functions in lesion shoulder areas may be attenuated by statins because of the high induction level of HMG-CoA reductase in these cells. HMG-CoA reductase also plays a role in the regulation of cell surface integrins CD11a and CD18, which bind to intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells. These integrins upregulated in LMD cells, and statins have been shown to downregulate CD11a and CD18 in cell culture.23 In addition, HMG-CoA reductase also functions in cell movements mediated by CD43,24 which was upregulated in LMD cells. Thus, DNA array analysis suggests that statin therapy may have favorable effects through these mechanisms, which should reduce monocyte-macrophage activity and trafficking in atherosclerotic lesions.
Other upregulated genes included CSF receptors, interleukin receptors, calmodulin, iNOS, extracellular SOD, and novel p53 target gene IRF-5. We have also previously demonstrated with DNA array analysis that some well known macrophage genes, such as apoE, TIMPs and VEGF receptor-2, were upregulated in lesion macrophages.6 Activation of these genes indicates that growth factor activities, inflammatory mediators, and oxidative stress play important roles in the microenvironment of lesion macrophages. On the other hand, expression of genes, such as VEGF, tissue factor pathway inhibitor 2, and apolipoproteins C1 and C2, were decreased, indicating less efficient vascular maintenance and increased susceptibility to thrombosis. It is important to note that genes associated with increased lipid uptake, such as scavenger receptors (1.7-fold induction), were not significantly upregulated in the LMD samples.
It is concluded that LMD can be used to dissect small cell populations from atherosclerotic lesions and that these cells can be used for DNA array analysis. Results showed that, among other genes, HMG-CoA reductase was highly upregulated in lesion macrophage-rich areas, which may explain some beneficial effects of statins not related to their lipid-lowering activity. Also, additional potential targets for therapy of cardiovascular diseases were identified.
| Acknowledgments |
|---|
We thank Seija Sahrio, Anneli Miettinen, and Marja Poikolainen for technical assistance and the staff at the Kuopio University Hospital for the collection of human samples. This study was supported by grants from Finnish Academy, Sigrid Juselius Foundation, and Finnish Foundation for Cardiovascular Research.
Received August 4, 2003; accepted October 6, 2003.
| References |
|---|
|
|
|---|
2. Shiffman D, Mikita T, Tai JT, Wade DP, Porter JG, Seilhamer JJ, Somogyi R, Liang S, Lawn RM. Large scale gene expression analysis of cholesterol-loaded macrophages. J Biol Chem. 2000; 275: 3732437332.
3. Wuttge DM, Sirsjo A, Eriksson P, Stemme S. Gene expression in atherosclerotic lesion of ApoE deficient mice. Mol Med. 2001; 7: 383392.[Medline] [Order article via Infotrieve]
4. McCaffrey TA, Fu C, Du B, Eksinar S, Kent KC, Bush HJ, Kreiger K, Rosengart T, Cybulsky MI, Silverman ES, Collins T. High-level expression of egr-1 and egr-1-inducible genes in mouse and human atherosclerosis. J Clin Invest. 2000; 105: 653662.[Medline] [Order article via Infotrieve]
5. Faber BC, Cleutjens KB, Niessen RL, Aarts PL, Boon W, Greenberg AS, Kitslaar PJ, Tordoir JH, Daemen MJ. Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res. 2001; 89: 547554.
6. Hiltunen MO, Tuomisto T, Niemi M, Bräsen JH, Rissanen TT, Törönen P, Vajanto I, Ylä-Herttuala S. Changes in gene expression in atherosclerotic plaques analyzed using DNA array. Atherosclerosis. 2002; 165: 2332.[CrossRef][Medline] [Order article via Infotrieve]
7. Kolble K. The LEICA microdissection system: design and applications. J Mol Med. 2000; 78: B24B25.[Medline] [Order article via Infotrieve]
8. Trogan E, Choudhury RP, Dansky HM, Rong JX, Breslow JL, Fisher EA. Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2002; 99: 22342239.
9. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A. 1990; 87: 69596963.
10. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, Am Heart Association. Arterioscler Thromb Vasc Biol. 1995; 15: 15121531.
11. Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch. 2000; 437: 396405.[CrossRef][Medline] [Order article via Infotrieve]
12. Laurema A, Heikkila A, Keski-Nisula L, Heikura T, Lehtolainen P, Manninen H, Tuomisto TT, Heinonen S, Yla-Herttuala S. Transfection of oocytes and other types of ovarian cells in rabbits after direct injection into uterine arteries of adenoviruses and plasmid/liposomes. Gene Ther. 2003; 10 (7): 580584.[CrossRef][Medline] [Order article via Infotrieve]
13. Laukkanen J, Lehtolainen P, Gough PJ, Greaves DR, Gordon S, Ylä-Herttuala S. Adenovirus-mediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modified low-density lipoprotein degradation and foam-cell formation in macrophages. Circulation. 2000; 101: 10911096.
14. Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, Xiao H, Rogers KE, Wan JS, Jackson MR, Erlander MG. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med. 1999; 5: 117122.[CrossRef][Medline] [Order article via Infotrieve]
15. Tuimala J, Laine MM, eds. DNA Microarray Data Analysis. Espoo, Finland: Finnish IT Center for Science; 2003.
16. Claverie JM. Computational methods for the identification of differential and coordinated gene expression. Hum Mol Genet. 1999; 8: 18211832.
17. Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Narvanen O, Manninen H, Rasanen H, Hippelainen M, Alhava E, Yla-Herttuala S. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med. 2002; 4: 371380.[CrossRef][Medline] [Order article via Infotrieve]
18. Hwang DM, Dempsey AA, Wang RX, Rezvani M, Barrans JD, Dai KS, Wang HY, Ma H, Cukerman E, Liu YQ, Gu JR, Zhang JH, Tsui SK, Waye MM, Fung KP, Lee CY, Liew CC. A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. Circulation. 1997; 96: 41464203.
19. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T, Ylä-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: Colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol. 1998; 18: 157167.
20. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990; 343: 425430.[CrossRef][Medline] [Order article via Infotrieve]
21. Angelin B. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in mouse peritoneal macrophages. Biochem J. 1988; 255: 529534.[Medline] [Order article via Infotrieve]
22. Palinski W, Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol. 2002; 22 (11): 17451750.
23. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MAJ, Yasukochi Y, Numano F. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 2001; 21 (7): 11651171.
24. Gubina E, Chen T, Zhang L, Lizzio EF, Kozlowski S. CD43 polarization in unprimed T cells can be dissociated from raft coalescence by inhibition of HMG CoA reductase. Blood. 2002; 99: 25182525.
This article has been cited by other articles:
![]() |
B. D. Lamon and D. P. Hajjar Inflammation at the Molecular Interface of Atherogenesis: An Anthropological Journey Am. J. Pathol., November 1, 2008; 173(5): 1253 - 1264. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Tuomisto, H. Lumivuori, E. Kansanen, S.-K. Hakkinen, M. P. Turunen, J. V. van Thienen, A. J. Horrevoets, A.-L. Levonen, and S. Yla-Herttuala Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2 Cardiovasc Res, April 1, 2008; 78(1): 175 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Ashley, J. M. Spin, R. Tabibiazar, and T. Quertermous Frontiers in Nephrology: Genomic Approaches to Understanding the Molecular Basis of Atherosclerosis J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2853 - 2862. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Sluimer, N. Kisters, K. B. Cleutjens, O. L. Volger, A. J. Horrevoets, L. H. van den Akker, A.-P. J. Bijnens, and M. J. Daemen Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery Physiol Genomics, August 20, 2007; 30(3): 335 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. L. Volger, J. O. Fledderus, N. Kisters, R. D. Fontijn, P. D. Moerland, J. Kuiper, T. J. van Berkel, A.-P. J.J. Bijnens, M. J.A.P. Daemen, H. Pannekoek, et al. Distinctive Expression of Chemokines and Transforming Growth Factor-{beta} Signaling in Human Arterial Endothelium during Atherosclerosis Am. J. Pathol., July 1, 2007; 171(1): 326 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Cho, P. Shashkin, C. A. Gleissner, D. Dunson, N. Jain, J. K. Lee, Y. Miller, and K. Ley Induction of dendritic cell-like phenotype in macrophages during foam cell formation Physiol Genomics, April 24, 2007; 29(2): 149 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Miller, P. M. Ridker, P. Libby, and D. J. Kwiatkowski Atherosclerosis: The Path From Genomics to Therapeutics J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1589 - 1599. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Thomas, G. B. Sala-Newby, Y. Ismail, J. L. Johnson, G. Pasterkamp, and A. C. Newby Genomics of Foam Cells and Nonfoamy Macrophages From Rabbits Identifies Arginase-I as a Differential Regulator of Nitric Oxide Production Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 571 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Blanco-Colio, J. L. Martin-Ventura, F. Vivanco, J.-B. Michel, O. Meilhac, and J. Egido Biology of atherosclerotic plaques: What we are learning from proteomic analysis Cardiovasc Res, October 1, 2006; 72(1): 18 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Papaspyridonos, A. Smith, K. G. Burnand, P. Taylor, S. Padayachee, K. E. Suckling, C. H. James, D. R. Greaves, and L. Patel Novel Candidate Genes in Unstable Areas of Human Atherosclerotic Plaques Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1837 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.P.J.J. Bijnens, E. Lutgens, T. Ayoubi, J. Kuiper, A.J. Horrevoets, and M.J.A.P. Daemen Genome-Wide Expression Studies of Atherosclerosis: Critical Issues in Methodology, Analysis, Interpretation of Transcriptomics Data Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1226 - 1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chimenti, M. Pieroni, A. Russo, P. Sale, M. A. Russo, A. Maseri, and A. Frustaci Laser Microdissection in Clinical Cardiovascular Research Chest, October 1, 2005; 128(4): 2876 - 2881. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lutgens, B. Faber, K. Schapira, C. T.A. Evelo, R. van Haaften, S. Heeneman, K. B.J.M. Cleutjens, A. P. Bijnens, L. Beckers, J. G. Porter, et al. Gene Profiling in Atherosclerosis Reveals a Key Role for Small Inducible Cytokines: Validation Using a Novel Monocyte Chemoattractant Protein Monoclonal Antibody Circulation, June 28, 2005; 111(25): 3443 - 3452. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |